PBAC's latest decision on Amlodipine besylate with valsartan: Recommended with restriction (2008). Considered for Hypertension in patients who are not adequately controlled with either amlodipine or valsartan monotherapy.
PBAC outcome
Recommended with restriction
Restricted
ICER (AUD/QALY)
Cost-min
cost-minimisation analysis
Submissions
1
first 2008
Submissions
1
2008 → 2008
Eligible population
patients who are not adequately controlled with either amlodipine or valsartan monotherapy
Therapy area
Cardiovascular
Line of therapy
Not applicable
Evidence base
RCT
Primary endpoint
null
Key trials
Study 2201, Study 2307, Fogari et al
Comparator
amlodipine and valsartan at equivalent doses
Economic model
Cost-minimisation
ICER note
Cost-minimisation analysis performed; no ICER calculated by design